CAMBRIDGE, Mass.--(BUSINESS WIRE)--Glympse Bio, Inc., a life science company developing in vivo activity sensors to transform disease monitoring, announced today that it has been named by FierceMedTech as one of 2018’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
Glympse, a spin-out from the laboratory of Sangeeta Bhatia, M.D., Ph.D. at the Massachusetts Institute of Technology, has developed a novel platform of highly tunable bioengineered activity sensors to query the body for disease status and report out clinically relevant insights rapidly and noninvasively. In October 2018, the company announced a $22 million Series A financing round to advance its lead indication targeting non-alcoholic steatohepatitis (NASH) - a growing pandemic that causes fibrosis and scarring of the liver – believed to afflict more than 100 million people worldwide and 15 million in the United States alone. The Company’s development pipeline features programs in a variety of cancers, immune and infectious diseases.
“We are honored to be recognized for our novel approach to transforming disease monitoring for patients, providers, and society,” said Caroline J Loew, Ph.D., President and Chief Executive Officer. “We look forward to continuing to advance into the clinic and moving forward our innovative development model.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity. An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, FierceMedTech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceMedTech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
ABOUT GLYMPSE BIO, INC.
Glympse Bio is pioneering an in
vivo sensing technology dedicated to transforming disease
monitoring. The company has built a product engine enabling rapid
development of tunable and bioengineered activity sensors for multiple
indications including fibrosis, cancer, immunology and infectious
diseases. The technology has been validated in 10 different diseases
using multiple delivery methods and a broad range of analytical
readouts. Glympse aims to improve healthcare globally by serving the
needs of patients, clinicians, researchers, drug developers, and payors
to help advance the science and our understanding of human diseases. The
company is based at the Lab Central incubator in Cambridge, MA. For more
information, please visit http://www.glympsebio.com.
ABOUT FIERCEMEDTECH
FierceMedTech keeps biopharma
executives, device developers, engineers, and researchers updated on the
must-know news, trends and developments in medical technology. More than
90,000 top industry professionals rely on FierceMedTech for an insider
briefing on the day's top stories.
